Page 84 - 2022_02-Haematologica-web

O. di Martino et al.
may incompletely activate the maturation pathways regu- lated by the retinoid receptors and that additional, unreal- ized potential may exist for retinoids in the treatment of forms of acute myeloid leukemia other than non-acute promyelocytic leukemia. In particular, myeloid maturation programs may be augmented by correctly activated retinoic X receptors and cells with monocytic potential may be sus- ceptible to retinoid-induced maturation. An efficient, con- stitutively active RXRA variant may enable further elucida- tion of this potential.
Disclosures
No conflicts of interest to disclose.
Contributions
JSW, OdM and MAF designed and performed experiments, and wrote the manuscript. GH, SS, AV, MPMG, and MR designed and performed experiments.
Acknowledgments
We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, (MO, USA). for the use of the Flow Cytometry Core. The Siteman Cancer Center is supported in part by a National Cancer Institute Cancer Center Support grant (P30 CA91842). We thank Christopher Miller, Sai Ramakrishnan, Deborah Laflamme, Conner York, and Sangeetha Vadivelu for technical assistance.
Funding
This work was supported by National Institutes of Health grant R01 HL128447 (JSW), by the Siteman Investment Program (JSW), the Washington University SPORE DRP (JSW and MAF), the Children’s Discovery Institute (JSW), the Alex’s Lemonade Stand Foundation Young Investigator Award (MAF), the National Institutes of Health 5K12HD07622408 (MAF), and grants from the Spanish Ministerio de Ciencia e Innovación (MCI) (SAF2017- 90604-REDT-NurCaMeIn, RTI2018-095928-BI00) (MR).
References
1.Oren T, Sher JA, Evans T. Hematopoiesis and retinoids: development and disease. Leuk Lymphoma. 2003;44(11):1881-1891.
2. Evans T. Regulation of hematopoiesis by retinoid signaling. Exp Hematol. 2005;33(9): 1055-1061.
3. Ricote M, Snyder CS, Leung HY, Chen J, Chien KR, Glass CK. Normal hematopoiesis after conditional targeting of RXRalpha in murine hematopoietic stem/progenitor cells. J Leukoc Biol. 2006;80(4):850-861.
4. Welch JS, Klco JM, Gao F, et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9): 796-800.
5. Di Martino O, Niu H, Hadwiger G, et al. Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica. 2021;106(4):1008-1021.
6. Martino OD, Welch JS. Retinoic acid recep- tors in acute myeloid leukemia therapy. Cancers. 2019;11(12):1915
7. Lubbert M, Grishina O, Schmoor C, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 x 2, phase II trial. J Clin Oncol. 2020:38(3):257-270.
8. vSchlenk RF, Frohling S, Hartmann F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18(11):1798-1803.
9. McKeown MR, Corces MR, Eaton ML, et al. Super-enhancer analysis defines novel epige- nomic subtypes of non-APL AML Including an RARalpha dependency targetable by SY- 1425, a potent and selective RARalpha ago- nist. Cancer Discov. 2017;7(10):1136-1153.
10.Sakamoto K, Imamura T, Yano M, et al. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARalpha promot- er region. Blood Cancer J. 2014;4(4):e205.
11.Niu H, Chacko J, Hadwiger G, Welch JS. Absence of natural intracellular retinoids in
mouse bone marrow cells and implications for PML-RARA transformation. Blood Cancer J. 2015;5(2):e284.
12. Menendez-Gutierrez MP, Roszer T, Fuentes L, et al. Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling. J Clin Invest. 2015;125(2):809- 823.
13. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quan- tification. Nat Biotechnol. 2016;34(5):525- 527.
14. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowl- edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
16. Ghosh JC, Yang X, Zhang A, et al. Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc Natl Acad Sci U S A. 2002;99(9):5842- 5847.
17. Lee WY, Noy N. Interactions of RXR with coactivators are differentially mediated by helix 11 of the receptor's ligand binding domain. Biochemistry. 2002;41(8):2500- 2508.
18. Cordeiro TN, Sibille N, Germain P, et al. Interplay of protein disorder in retinoic acid receptor heterodimer and its corepressor regulates gene expression. Structure. 2019;27(8):1270-1285.
19. Gao W, Liu J, Hu M, et al. Regulation of pro- teolytic cleavage of retinoid X receptor- alpha by GSK-3beta. Carcinogenesis. 2013;34(6):1208-1215.
20. Fadel L, Reho B, Volko J, et al. Agonist bind- ing directs dynamic competition among nuclear receptors for heterodimerization with retinoid X receptor. J Biol Chem. 2020;295(29):10045-10061.
21. Devarakonda S, Gupta K, Chalmers MJ, et al. Disorder-to-order transition underlies the structural basis for the assembly of a tran- scriptionally active PGC-1alpha/ERRgamma complex. Proc Natl Acad Sci U S A. 2011;108(46):18678-18683.
22. Kersten S, Dong D, Lee W, Reczek PR, Noy N. Auto-silencing by the retinoid X receptor. J Mol Biol. 1998;284(1):21-32.
23. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell. 2000;5(2):289-298.
24. Hiromori Y, Aoki A, Nishikawa J, Nagase H, Nakanishi T. Transactivation of the human retinoid X receptor by organotins: use of site-directed mutagenesis to identify critical amino acid residues for organotin-induced transactivation. Metallomics. 2015;7(7): 1180-1188.
25. Halstead AM, Kapadia CD, Bolzenius J, et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-acti- vated receptors to drive urothelial prolifera- tion. Elife. 2017;6:e30862.
26. Brown AL, Wilkinson CR, Waterman SR, et al. Genetic regulators of myelopoiesis and leukemic signaling identified by gene profil- ing and linear modeling. J Leukoc Biol. 2006;80(2):433-447.
27.Purton LE. Roles of retinoids and retinoic acid receptors in the regulation of hematopoietic stem cell self-renewal and differentiation. PPAR Res. 2007;2007:87934.
28. Mullen EM, Gu P, Cooney AJ. Nuclear receptors in regulation of mouse ES cell pluripotency and differentiation. PPAR Res. 2007;2007:61563.
29. Taschner S, Koesters C, Platzer B, et al. Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood. 2007;109(3):971-979.
30. Yadav B, Pemovska T, Szwajda A, et al. Quantitative scoring of differential drug sen- sitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.
31. Bianchi N, Ongaro F, Chiarabelli C, et al. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem Pharmacol. 2000;60(1):31-40.
32. Niu H, Fujiwara H, di Martino O, et al. Endogenous retinoid X receptor ligands in mouse hematopoietic cells. Sci Signal. 2017;10(503):eaan1011.
426
haematologica | 2022; 107(2)